Advancing novel therapies for heart failure
Brano Therapeutics is a biotechnology spin-off from Duke-NUS Medical School in Singapore, focused on developing novel treatments for heart failure, including Heart Failure with preserved Ejection Fraction (HFpEF). The company is built on research identifying a distinct metabolic abnormality in failing hearts — where the heart becomes less efficient at processing key nutrients — and is developing compounds that restore metabolic regulation to reduce heart stiffness and improve cardiac function. Backed by Trinity Innovation Bioventure Singapore (TIBS), SEEDS (SG Growth Capital), SGInnovate, and Duke-NUS' LIVE Ventures, Brano aims to advance its lead program into clinical trials by 2029.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountMay 2026
Create a free account to see which investors have funded this company.
Create Free Account
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
Healthcare company applying technology to drug development by building nimble biotech subsidiarie...
Neuralink is building a brain-computer interface for medical needs and greater human potential.
